Features | Partner Sites | Information | LinkXpress
Sign In
FOCUS DIAGNOSTICS, INC.
RANDOX LABORATORIES
AB Sciex

Biomarker Improves Head and Neck Cancer Patient Prognosis

By Labmedica International staff writers
Posted on 31 Jan 2012
A molecular fingerprint in head and neck cancers can predict whether a patient's tumor will be life threatening.

The molecular fingerprint biomarker is considered particularly promising because it can detect the level of risk immediately following diagnosis. This biomarker could become a component of a new test to guide how aggressively those with head and neck tumors should be treated.

A study was performed at Albert Einstein College of Medicine of Yeshiva University (Bronx, NY, USA) and Montefiore Medical Center (Bronx, NY, USA), the University Hospital for Einstein. Tissue samples were taken from tumors and nearby healthy tissue of 123 head and neck cancer patients at Montefiore and levels of 736 microRNAs were measured. Of all the microRNAs measured, one in particular–miR-375– stood out for being the most down-regulated in head and neck tumors compared with its levels in adjacent normal tissue.

The 123 patients were ranked according to how extreme the difference was between the miR-375 in their tumor and in adjacent normal tissue, with that difference expressed as the ratio: miR-375 level in patient's tumor tissue divided by miR-375 level in patient's normal tissue. All patients were then followed throughout the course of their illness.

MiR-375 proved to be a highly useful biomarker for predicting disease outcome. The patients for whom the difference between their tumor and normal-tissue miR-375 levels was most extreme (i.e., the one-fourth of patients with the lowest ratios) were nearly 13 times more likely to die or 9 times more likely to experience distant spread (metastasis) of their cancer compared to patients with higher miR-375 ratios.

The findings were published online January 9, 2012, in the American Journal of Pathology.

Related Links:

Albert Einstein College of Medicine
Montefiore Medical Center


GREINER-BIO-ONE
ADVANCED INSTRUMENTS
PURITAN MEDICAL
BioConferenceLive

Channels

Hematology

view channel

Blood Donations Screened for Viruses Using Multiplex Assay

A global healthcare company was chosen to partner the Japanese Red Cross (JRC; Tokyo, Japan) for nucleic acid screening of the nation's blood supply. Under the terms of the 7-year agreement, the healthcare company, Grifols (Barcelona, Spain) will provide the JRC with its newest automation platform, the Procleix Panther... Read more

Pathology

view channel

Gene Profile Predicts Risk of Bladder Cancer Recurrence

A genomic study has pinpointed several markers that identify bladder cancer patients at risk of recurrence and that may be indicators of overall survival status. Nearly half of patients with bladder cancer experience recurrences, so reliable predictors of this recurrent phenotype are needed to guide surveillance and treatment.... Read more

Industry News

view channel

Beckman Coulter and hc1.com Enter Strategic Partnership for Innovative Healthcare Cloud System

The diagnostics division of Beckman Coulter (Brea, CA, USA) and hc1.com (Indianapolis, IN, USA) have announced a partnership to bring an innovative healthcare cloud-technology system to clinical laboratories. The system, hc1.com's "Healthcare Relationship Cloud," helps turn large amounts of clinical data into actionable... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.